MetaG1 Research Consortium

#phytochemicals #bioactive molecules #nutraceuticals Dear Colleagues, Phytochemicals and bioactive molecules are at the heart of the new wave. We, as a MetaG1 Research Consortium, are interested in the starting materials and intermediates of the following molecules. Kindly contact us if you can custom manufacture and supply starting materials and intermediates: 𝐜𝐨𝐧𝐭𝐚𝐜𝐭𝐮𝐬@𝐦𝐞𝐭𝐚𝐠1.𝐜𝐨𝐦 Any other related molecules and intermediates are also welcome! - 𝐐𝐮𝐞𝐫𝐜𝐞𝐭𝐢𝐧: Quercetin is a flavonoid found in many fruits and vegetables, known for its antioxidant properties and potential to support heart health and combat inflammation. - 𝐑𝐮𝐭𝐢𝐧: Rutin is a bioflavonoid that supports blood vessel health, possesses antioxidant properties, and helps the body to utilize vitamin C more efficiently. - 𝐑𝐞𝐬𝐯𝐞𝐫𝐚𝐭𝐫𝐨𝐥: Resveratrol, often associated with red wine, is a compound that has been linked to anti-aging effects, heart health benefits, and the potential to protect against certain diseases. - 𝐍𝐚𝐫𝐢𝐧𝐠𝐢𝐧: Naringin is a flavonoid found predominantly in grapefruits and other citrus fruits, known for its antioxidant activity and ability to influence metabolism and potentially support cardiovascular health. - 𝐀𝐩𝐢𝐠𝐞𝐧𝐢𝐧: Apigenin is a natural compound found in several plants, recognized for its anti-inflammatory, anti-cancer properties, and ability to promote relaxation and sleep. - 𝐃𝐢𝐨𝐬𝐦𝐢𝐧: Diosmin is a flavonoid primarily used to treat various vascular disorders, including hemorrhoids and venous insufficiency, by improving vein tone and reducing inflammation. - 𝐇𝐞𝐬𝐩𝐞𝐫𝐢𝐝𝐢𝐧: Hesperidin, found mainly in citrus fruits, is celebrated for its antioxidant benefits, ability to strengthen blood vessels, and potential to reduce inflammation and blood pressure levels. contactus@metag1.com #BioactiveMolecules #SupplyChain #Procurement #customsynthesis #PartnershipOpportunities #InnovationInHealthcare #custommanufacturing #organicchemistry #synthesis #processdevelopment #nutraceuticals

𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐟𝐨𝐫 𝐚𝐥𝐥: 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐬 𝐂𝐥𝐚𝐬𝐬𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦 (𝐁𝐂𝐒) Dear LinkedIn Friends, The Biopharmaceutics Classification System (BCS) is a pivotal framework in pharmaceutical development, guiding the categorization of drugs based on their 𝐬𝐨𝐥𝐮𝐛𝐢𝐥𝐢𝐭𝐲 𝐚𝐧𝐝 𝐩𝐞𝐫𝐦𝐞𝐚𝐛𝐢𝐥𝐢𝐭𝐲. This system, essential for drug formulation and regulatory processes, divides compounds into four distinct classes: 1. 𝐂𝐥𝐚𝐬𝐬 𝐈: High Solubility, High Permeability - These drugs are typically well absorbed and have an absorption rate that surpasses their excretion rate. 2. 𝐂𝐥𝐚𝐬𝐬 𝐈𝐈: High Permeability, Low Solubility - The bioavailability of these drugs is generally 𝐥𝐢𝐦𝐢𝐭𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞𝐢𝐫 𝐫𝐚𝐭𝐞 𝐨𝐟 𝐬𝐨𝐥𝐯𝐚𝐭𝐢𝐨𝐧. 3. 𝐂𝐥𝐚𝐬𝐬 𝐈𝐈𝐈: Low Permeability, High Solubility - While these drugs dissolve quickly, their absorption is limited by permeation rates. 4. 𝐂𝐥𝐚𝐬𝐬 𝐈𝐕: Low Solubility, Low Permeability - These drugs often exhibit poor bioavailability and are not well absorbed through the intestinal mucosa. 𝐖𝐡𝐲 𝐢𝐬 𝐁𝐂𝐒 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭? BCS plays a crucial role in early-phase drug discovery, helping to assess the risks of oral absorption. This information is vital for developing effective chemical and formulation strategies. Most of the #PROTACs fall into class IV compounds. Hence, PROTACs pose significant challenges due to their low solubility and permeability, leading to suboptimal patient outcomes and variable pharmacokinetics. To enhance oral absorption of these compounds, formulation strategies often focus on solubility/dissolution enhancement. 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐢𝐧 𝐁𝐂𝐒 𝐂𝐥𝐚𝐬𝐬 𝐈𝐕 For BCS Class IV compounds, the aim is to achieve supersaturation through various methods like forming micelles, nanoparticles, or amorphous particles. These techniques may increase drug transport across the intestinal membrane through several mechanisms, offering new research avenues and questions in pharmaceutical development. 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲 Understanding the BCS classification is crucial for drug hunter and pharmaceutical professionals as it guides the effective formulation and development of new drugs, ensuring higher success rates. With regards, Purushottam Dewang MetaG1 Research Consortium #Biopharmaceutics, #DrugDevelopment, #PharmaceuticalScience, #BCSClassification, #DrugSolubility, #DrugPermeability, #innovation #Pharmacokinetics, #FormulationStrategies, #PharmaInnovation, #ClinicalPharmacology, #MedicinalChemistry, #DrugDiscovery, #PharmaIndustry, #Pharmaceuticals

𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐃𝐫𝐮𝐠 𝐂𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬 (𝐀𝐃𝐂𝐬) Dear Linkedin Friends, Did we speak about ADCs, No? Then let us see it today. You will enjoy knowing basics of it. 1. 𝐁𝐚𝐜𝐤𝐠𝐫𝐨𝐮𝐧𝐝: Despite advancements in immunotherapy and cell therapies, chemotherapy is still the most common cancer treatment. Traditional chemotherapy drugs are powerful against cancer cells but may also harm healthy tissues, limiting their effectiveness. 2. 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐀𝐃𝐂𝐬: To address this issue, the concept of ADCs was developed. An ADC combines a monoclonal antibody (which specifically targets cancer cells) with a potent anti-cancer drug (payload). This approach aims to deliver the drug directly to cancer cells, minimizing damage to healthy cells. 3. 𝐇𝐢𝐬𝐭𝐨𝐫𝐢𝐜𝐚𝐥 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭:    - ADCs were first proposed in 1913 by Paul Ehrlich, but significant development began in 1975 with the advent of technology to produce monoclonal antibodies.   - The first generation of ADCs used traditional chemotherapy drugs as payloads but were not very effective due to insufficient potency and selectivity.   - The second generation used more potent tubulin inhibitors, which are effective against rapidly dividing cancer cells but less so against non-dividing cells.   - The third generation uses DNA-damaging agents, effective throughout the cell cycle, including against non-dividing cells. 4. 𝐂𝐮𝐫𝐫𝐞𝐧𝐭 𝐒𝐭𝐚𝐭𝐞 𝐨𝐟 𝐀𝐃𝐂𝐬:   - Currently, 15 ADC drugs are approved, and many are in clinical trials. Their payloads are mainly natural origin, with tubulin inhibitors being most common.   - Despite advancements, challenges like severe side effects and drug resistance persist, highlighting the need for better payloads with improved therapeutic indexes. 5. 𝐅𝐮𝐭𝐮𝐫𝐞 𝐃𝐢𝐫𝐞𝐜𝐭𝐢𝐨𝐧𝐬:   - Novel ADC payloads are being developed, including RNA inhibitors, Bcl-xL inhibitors, NAMPT inhibitors, and carmaphycins.   - Immune ADCs, using immunomodulators as payloads, are gaining attention for their role in tumor immunotherapy.   - Innovative strategies involve complex payloads like #PROTACs or photosensitizers, and combining multiple payloads targeting different aspects into a single antibody. Hope this introduces to you the ongoing evolution in #ADC research, aiming for more effective and safer cancer treatments. 𝑳𝒊𝒌𝒆𝒔, 𝒄𝒐𝒎𝒎𝒆𝒏𝒕𝒔 𝒂𝒏𝒅 𝒓𝒆𝒑𝒐𝒔𝒕 𝒂𝒓𝒆 𝒆𝒏𝒄𝒐𝒖𝒓𝒂𝒈𝒆𝒎𝒆𝒏𝒕𝒔! with regards, Purushottam Dewang MetaG1 Research Consortium #AntibodyDrugConjugates, #CancerTreatment, #Chemotherapy, #OncologyInnovation, #TargetedTherapy, #ADCsInCancer, ref for picture: https://lnkd.in/dJb8xP86 #MonoclonalAntibodies, #DrugDeliverySystems, #OncologyResearch, #HealthcareEvolution, #MedicalBreakthroughs, #Immunotherapy, #CellTherapies, #CancerResearch, #ClinicalTrials, #DrugDevelopment, #OncologyAdvancements, #PrecisionMedicine, #CancerTherapy

Happy New Year 2024! 🤝 Pharmatech, Biotech, Agritech Consortium 🌿 If alone you are feeling limitations to grow then ... Shake hands with sustainability, innovation and business growth. Curious about joining the fastest-growing consortium in the industry? 📩 Contact us: contactus@metag1.com Discover infinite possibilities with MetaG1. Follow Purushottam Dewang MetaG1 Research Consortium CropG1 Agro Research & Development Pvt Ltd #medicinalchemistry #drugdiscovery #agritech #pharmatech #biotech #innovation #CRO #CMO #CDMO #contractresearchorganization #Contractresearch #outsourcing #newyear2024 #MetaG1 #CropG1 #chemistry #

“𝐉𝐁𝐈-802 : Our Clinical Candidate” Dear LinkedIn-Family Friends,  Yesterday you heard great good news about the outcome of phase I clinical trial our drug molecule JBI-802. You applauded this success whole-heartedly, whooping 200+ likes (appreciations), and around 50+ messages (direct and in comments). This love and dialogue keeps me talking to you. Yesterday we saw a technical side of this achievement. Is having a strong hypothesis (scientific-side) enough for success in drug discovery? No, it's not "only" the science that drives the project to success. The science and hypothesis are certainly important but the "team" is the cornerstone of drug discovery success. Overall drug discovery being a highly multidisciplinary and complex subject, a very delicately netted fabric of coordination among different groups is very important in drug discovery and development projects. None of the elements of the team is of lesser importance in overall success. The complex fabric of a team involves several individuals and departments at different execution levels. Top management, Key Opinion Leaders/advisors, Higher management, Middle management, executives, and assistants. Various departments, medicinal chemistry, in vivo biology, in vitro biology, computational chemistry, structural biology, informatics and in slilico chemistry, animal studies, toxicology, analytical, compound registration (compound management) and data management, and project management, Intellectual property all play key role. Being the co-inventor of the three clinical candidates I wish to share with you that at the foundation of our successes lies a wonderful exceptionally well-coordinated team. The first two of our clinical candidates, ASN001, a novel non-steroidal CYP17 lyase inhibitor; and ASN007(ERAS 007, ERK-IN-3), RAS-and RAF-mutant active selective ERK1/2 inhibitor, were client-programs (means CRO drug discovery project outsourced to us). When projects are outsourced or are client projects and are not in-house projects, a different angle of client alignment with CRO-teams comes into the game. I must tell you that in both cases we (as CRO-team) won the hearts of the client and should acknowledge that our client-side team was also wonderful. Both teams were so well-aligned, in the two projects we delivered clinical candidates, even today, after leaving the organisation and departing, we all feel that we were utterly fortunate to have such a wonderful client and internal team. When you play some game, say football, or basketball every player is important, the similar way we enjoyed these clinical candidates. Our third project (JBI-802) was Jubilant's internal own drug discovery project. I will someday explain the modality of the successful execution of internal and CRO-drug discovery projects. That will be fun! Have a great time.  JBI-802 related posts: https://lnkd.in/gk8usYze  https://lnkd.in/djTgFsz8 with the best regards,  Purushottam Dewang MetaG1 Research Consortium

We have great good news to share - Super Excited! Milestone!! Dear LinkedIn-family Friends, I am super excited to share the good news with you all. This is an outstanding milestone in journey as a medicinal chemist. The preliminary results from a Phase I trial of JBI-802 in advanced cancer patients are announced.** Proud to be the co-inventor of this clinical drug candidate. I spoke about our this clinical candidate, JBI-802, some time back.* Details of the phase-I outcome are as follows: 1. JBI-802 Details: Jubilant Therapeutics Inc. is developing JBI-802, a CoREST (Co-repressor of Repressor Element-1 Silencing Transcription) inhibitor. It has dual activity on LSD1 and HDAC6 enzymes. To know more about this drug candidate read my earlier post, link is given at the end*. 2. Phase I Trial Results: - The trial involved 11 patients with advanced cancer. - The drug showed a dose-proportional increase in effectiveness across different doses. - It led to a decrease in platelets, indicating effective LSD1 inhibition. - Unlike LSD1-only inhibitors, JBI-802 didn’t cause significant adverse events like anemia or Dysgeusia (taste disorders). 3. Effectiveness in NSCLC Patients: - Two Non-small Cell Lung Cancer (NSCLC) patients who had previously not responded to immunotherapy (nivolumab + ipilimumab) showed positive responses to JBI-802. - One patient with a STK11 mutation (which typically reduces immunotherapy effectiveness) showed a 39% decrease in lung tumor size. - The other patient had a reduction in liver metastasis by over 50% and improvement in related symptoms. 4. Doctor’s Observation: Dr. @Alexander Starodub noted the remarkable anti-tumor activity in these NSCLC patients, especially considering their poor prognosis. The 10 mg dose of JBI-802 was well-tolerated and showed a good therapeutic index. 5. Potential for Hematological Malignancies: The decrease in platelets indicated that JBI-802 might be effective in blood-related cancers like Essential Thrombocythemia (ET) and Myeloproliferative Neoplasms (MPN/MDS) with thrombocytosis. 6. Future Plans: A follow-up Phase I/II study is planned to investigate JBI-802 as a potential treatment for MPN/ET and MPN/MDS with thrombocytosis. In summary, the early trial results of JBI-802 suggest it has potential as a therapy for cancer patients who are resistant to current immunotherapies, particularly for lung cancers and blood-related cancers. Grateful to be part of this innovative team: Sridharan Rajagopal , Dhanalakshmi Sivanandhan , Sreekala Nair; Mohd Zainuddin; Dr. Sunil Mohire, Subramanyam Tantry , Mahanandeesha Hallur , Durga prasanna kumar CH, Ramesh Mullangi With regards, Purushottam Dewang MetaG1 Research Consortium *https://lnkd.in/djTgFsz8 **https://lnkd.in/dd4yyt8i #clinicalcandidate #clinicaltrials #clinicalresearch #JubilentTherapeutics #BiotechInnovation #JBI802 #MetaG1 #medicinalchemistry #drugdiscovery #innovation #success

"2024 Good Morning" As we step into 2024, let's take a moment to appreciate the beauty of new beginnings. This stunning sunrise amidst lush greenery symbolizes the fresh opportunities and growth that lie ahead. It's a reminder of the endless possibilities that each new day brings. This year, let's commit to nurturing our personal and professional growth, just like the sun nurturing the earth. Let's be bold, be innovative, and be ready to embrace whatever comes our way. Here's to a year of prosperity, success, and vibrant new adventures. Happy 2024, everyone! 🌿🌞 #NewYear2024 #GrowthMindset #NewBeginnings #CareerGoals #innovation #drugdiscovery #medicinalchemistry #careergrowth #outsourcing #cro #contractmanufacturing #contractresearchorganization

Preparing for an interview? Dear LinkedIn-family Friends, We have been discussing as part of "cafe-CRO" chemistry careers in last few posts*. Let us today talk about interview - for both, interviewer and interviewee, the following insights should help to prepare. Candidates are usually assessed not only for their technical skills but also for their problem-solving abilities, teamwork, and adaptability. Here are important insights to prepare for interview: Technical and Experience-Based Questions 1. Describe your experience with synthetic chemistry. (to understand background and areas of expertise.) 2. Can you walk me through a complex synthesis you worked on? (judges problem-solving skills and technical knowledge.) 3. How do you stay updated with the latest developments in synthetic chemistry? (the commitment to continuous learning.) 4. Have you ever encountered a reaction that did not proceed as expected? How did you handle it? (problem-solving and adaptability.) 5. What safety protocols do you follow during chemical synthesis? (understanding of lab safety.) 6. Can you describe a time when you had to scale up a reaction? What challenges did you face? (experience with scaling up processes.) Teamwork and Communication 7. Describe a situation where you had to explain a complex chemical concept to a non-expert. (Tests communication skills.) 8. Can you give an example of how you have handled a disagreement with a colleague in the lab? (Looks at conflict resolution and interpersonal skills.) Adaptability and Problem-Solving 9. Describe a project where things didn’t go as planned. How did you adapt? (Assesses resilience and flexibility.) 10. How do you prioritize tasks when working on multiple projects? (Gauges organizational skills.) 11. Have you ever had to learn a new technique or tool quickly for a project? How did you approach it? (Tests learning agility and adaptability.) Company-Specific and Future-Oriented Questions 12. Why are you interested in joining our multinational chemistry synthesis group? (Looks for motivation and alignment with company’s values.) 13. Where do you see your career in synthetic chemistry in the next five years?(Assessing career aspirations and long-term potential.) Scenario-Based Questions 14. If given an unfamiliar synthesis task, how would you approach it? (Tests approach to new challenges.) 15. Imagine a scenario where a synthesis method you proposed is not well-received by the team. How would you handle it? (Looks at the response to feedback and teamwork dynamics.) Closing Questions 17. Do you have any questions for me or about our company/group? (Gives chance to candidate) * https://lnkd.in/gRgpVhE6 and https://lnkd.in/gZ4XVxdY Follow at Purushottam Dewang MetaG1 Research Consortium, CropG1 Agro Research & Development Pvt Ltd #OrganicChemistry #ChemicalSynthesis #MedicinalChemistry #DrugDiscovery #ChemistryInnovation #CareerGrowth #ScienceCommunication #interview #jobsearch #Job #jobseekers #MetaG1 #CropG1

Dear Linkedin-family Friends We have been discussing extracellular Targeted Protein Degradation (eTPD). Yesterday we saw 6 eTPD strategies*. Today let us see the commercialization status of those strategies in the attached table. Here is the list of abbreviations used in the table and their meanings: - ASGPR: Asialoglycoprotein Receptor - AbTAC: Antibody-Based PROTAC - ATAC: ASGPR-Targeting Chimera - CI-M6PR: Cation-Independent Mannose 6-Phosphate Receptor - EGFR: Epidermal Growth Factor Receptor - EPOR: Erythropoietin Receptor - FcRn: Neonatal Fc Receptor - IGF1R: Insulin-Like Growth Factor 1 Receptor - LYTAC: Lysosome-Targeting Chimera - Nb: Nanobody - PCNA: Proliferating Cell Nuclear Antigen - PDGF: Platelet-Derived Growth Factor - PROTAB: Proteolysis-Targeting Antibody - PROTAC: Proteolysis-Targeting Chimera - PTK7: Protein Tyrosine Kinase 7 - REULR: Receptor Elimination by E3 Ubiquitin Ligase Recruitment - TRIM21: Tripartite Motif-Containing 21 - VEGF: Vascular Endothelial Growth Factor Follow Purushottam Dewang and MetaG1 Research Consortium. “Like and RESHARE” Interested businesses CRO/CMO/CDMO: contactus@metag1.com Earlier interesting posts on the same subject (eTPD) Differences between #iTPD and #eTPD: https://lnkd.in/gUGAzvk9 *Six eTPD strategies: https://lnkd.in/gybyE3mz #MetaG1  #PROTACS #eTPD Ref: https://lnkd.in/dT5jk8xF #PROTACs #proteindegradation #innovation #medicinalchemistry #drugdiscovery #drugdesign #CRO #contractmanufacturing #contractresearchorganization